Biotech stock valuations wavered in October with the average IPO return in the US nearing negative territory, but observers say there is still a healthy market for new biopharma offerings in 2018 and into next year.
Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.
In 2017, the top 15 pharma companies paid their CEOs a total of $251m in salary and other benefits, while reporting net income of $56.5bn. But while income was down 41% on 2016, compensation declined by a more modest 9%. In this infographic, Scrip provides a snapshot of these companies' leaders and the businesses they oversee.
High valuations, an uncertain biopharma macro environment and widespread use of US tax reform benefits for share buybacks and capital investments resulted in less major M&A than expected. Opinions vary widely on whether 2019 will be any different.
Constantine Chinoporos, Boston Pharmaceuticals’ CBO, talks to Scrip about its deal strategy and how it intends to build its pipeline over the next few years, liberated from the constraints of portfolio management.
CGRP inhibitors were a hot topic during third quarter earnings calls, with Amgen and Teva talking about reimbursement progress, while Lilly marked progress for its add-on treatment, Allergan calmed fears about Botox's migraine sales, and Alder said its intravenous drug is on track.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.